Eclipse Life Sciences has enrolled and dosed the first patient in the BETTIS-1 phase 2 clinical trial investigating the EC-104 implant for the treatment of diabetic macular edema, according to a press release.
The randomized, controlled, double-masked trial will compare the extended release of 0.14 mg and 0.092 mg doses of EC-104 (fluocinolone acetonide) with Ozurdex (dexamethasone intravitreal implant, AbbVie) in patients with DME who had a previous suboptimal clinical response to intravitreal anti-VEGF therapy. Enrolled patients have also previously been treated with locally administered